about
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseasesMolecular prognostic prediction in liver cirrhosisFuture microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.Use of big data in drug development for precision medicine.Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.The new field of 'precision psychiatry'.The mechanisms of radioresistance in esophageal squamous cell carcinoma and current strategies in radiosensitivityCost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Clinical Applications of Autophagy Proteins in Cancer: From Potential Targets to Biomarkers.Serum microRNA-150 predicts prognosis for early-stage non-small cell lung cancer and promotes tumor cell proliferation by targeting tumor suppressor gene SRCIN1.Mass spectrometry-assisted gel-based proteomics in cancer biomarker discovery: approaches and application.Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.CD90 positive cells exhibit aggressive radioresistance in esophageal squamous cell carcinomaMetabolomic biomarkers of pancreatic cancer: a meta-analysis study.Circulating biomarker for malignant pleural mesothelioma diagnosis: pay attention to study design.Cancer-type dependent expression of CK2 transcripts.Validation of Customized Cancer Panel for Detecting Somatic Mutations and Copy Number Alterations.Progranulin and its biological effects in cancer.The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) Resource in Neuro-Oncology.Disposable inkjet-printed electrochemical platform for detection of clinically relevant HER-2 breast cancer biomarker.Pyrenyl carbon nanostructures for ultrasensitive measurements of formaldehyde in urine.Redox Cycling Realized in Paper-Based Biochemical Sensor for Selective Detection of Reversible Redox Molecules Without Micro/Nano Fabrication Process.Sialyltransferase-Based Chemoenzymatic Histology for the Detection of N- and O-Glycans.Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy.Plasmalogen lipids: functional mechanism and their involvement in gastrointestinal cancer.Evolution of proteomic biomarker for chronic liver disease: Promise into reality.Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs).Live-single-cell phenotypic cancer biomarkers-future role in precision oncology?High-accuracy determination of internal circadian time from a single blood sampleChanges in Membrane Protein Clustering in Peripheral Lymphocytes in an Animal Model of Depression Parallel Those Observed in Naïve Depression Patients: Implications for the Development of Novel Biomarkers of Depression
P2860
Q26752864-570BC19E-0CD6-4F56-B81C-F4BB57C8C60CQ26784251-08E31522-6625-4798-BAA5-1F762EDD7401Q30357091-E7328F69-DB93-4921-B0F4-5F14CFA184B8Q31115480-4FCFA2BC-D112-4931-A841-7C73819A4532Q31138564-1039D63C-7904-4CBD-BBD9-FD694601455BQ33560453-69CD965F-7763-4CBA-ACD8-FE97215D8880Q33571306-A73DA289-C940-41B6-B520-BF6D6E558A14Q33920344-AA532FFB-B101-4498-929E-9855B4158376Q37619866-5CD998BD-B6A7-48DE-9398-96F48AD4C0CDQ38907580-525F0A3E-E06D-4FA7-A148-555BCD02EB76Q39428280-DAB36B4C-1695-4ED7-8A77-6B2044F4ED34Q40048290-5BA89D63-91C1-47C3-8788-56DFFFDF76C9Q41173805-BF4E7FBE-4697-4EE5-B552-94DF7C1375A3Q41593380-FF541E8F-ADDC-4015-B75F-B60EEFF413E7Q41603225-296C744E-26C3-40F7-A2A7-FADACD58063AQ41921861-DA6DD2F6-770F-48D6-8FEA-17BFBAEBCD59Q42138943-30DA79B5-4E3D-45A3-BD8E-7E1D1469F9D2Q42154484-7A0D812F-6F4E-486D-813B-3103125D8F3DQ42369288-E12F7587-BBC1-411C-A46B-E8C31E5A2D65Q47114281-EFA5F23C-1D16-4D9D-8F3C-7826EA7BA698Q47201395-9E2ADB5A-4931-49C7-89B4-D331B97F2332Q47425664-B1C34431-3E47-4239-84C3-2B1D823250C3Q47755845-354D8D1A-CDE2-44CA-ADC2-E538E4CC640AQ50055468-BB32EDBE-FF8C-4B65-A55D-B3307CB945AFQ50708872-4031261F-80BE-4325-B14A-1991EEBE77B7Q51745703-33864801-664C-404D-A824-9EFF0D31E72DQ52344895-30F1129A-4240-4EC5-90E7-D3A8E5B95357Q53703015-EC1CE4B4-34E1-4FD0-9433-04DD7FAF48B0Q54942543-D70B361F-9D77-4CB5-BD11-5EB3D462AF37Q55091571-DDE1214D-6444-4A7E-92FA-AB3E570991D4Q55232303-52CFF624-C34F-47A2-AD35-6EB1E5144A8AQ55343172-E1CB3D63-F6C2-4195-BD10-65544520592FQ55397731-63C2B0ED-248A-4540-BD21-596F706C8F12Q56965075-AFDB62AB-A89A-4646-970D-470316E1F016Q58122196-7045DA6E-98EC-41E1-BDE9-D2A2AB5D945F
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cancer biomarker discovery and validation.
@ast
Cancer biomarker discovery and validation.
@en
type
label
Cancer biomarker discovery and validation.
@ast
Cancer biomarker discovery and validation.
@en
prefLabel
Cancer biomarker discovery and validation.
@ast
Cancer biomarker discovery and validation.
@en
P2093
P2860
P1476
Cancer biomarker discovery and validation.
@en
P2093
Nicolas Goossens
Shigeki Nakagawa
Xiaochen Sun
Yujin Hoshida
P2860
P304
P356
10.3978/J.ISSN.2218-676X.2015.06.04
P577
2015-06-01T00:00:00Z